Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Biology and Signal Transduction

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
Junko Murai
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shar-Yin N. Huang
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amèlie Renaud
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiping Zhang
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiuping Ji
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunichi Takeda
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Morris
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beverly Teicher
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Doroshow
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Pommier
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0803 Published February 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently reported that several PARP inhibitors have an additional cytotoxic mechanism by trapping PARP–DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacologic concentrations. Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP–DNA trapping. Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clinical PARP inhibitors, olaparib and rucaparib, using biochemical and cellular assays in genetically modified chicken DT40 and human cancer cell lines. Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP–DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP–DNA complexes. The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2. Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient. BMN 673 is also approximately 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents methyl methane sulfonate (MMS) and temozolomide. Our study demonstrates that BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes. Mol Cancer Ther; 13(2); 433–43. ©2013 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Received September 24, 2013.
  • Revision received December 2, 2013.
  • Accepted December 8, 2013.
  • ©2013 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (2)
February 2014
Volume 13, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
Mol Cancer Ther February 1 2014 (13) (2) 433-443; DOI: 10.1158/1535-7163.MCT-13-0803

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
Mol Cancer Ther February 1 2014 (13) (2) 433-443; DOI: 10.1158/1535-7163.MCT-13-0803
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ABCB1 Confers Cross-Resistance to Cabazitaxel and Docetaxel
  • Proinflammatory Cytokines and Drug Resistance
  • IGF2 Overexpression Predicts IGF1R/INSR Inhibitor Response
Show more Cancer Biology and Signal Transduction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement